Payment overview · 2025
General Payments
$314.29
17 reported records · 6 companies
Healthcare provider profile · identity verified
Jeffrey Luna, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LIVINGSTON, TX · NPI 1144540253
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Luna, M.D. received $314.29 in general payments during 2025 across 17 reported records.
Sumitomo Pharma America, Inc. accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $142.63 | 45.4% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $62.03 | 19.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.01 | 14.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.16 | 11.2% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.57 | 5.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $12.89 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.29 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $142.63 | 8 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $62.03 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $12.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 154 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 262 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
154 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 976 | 264 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 145 |
| Furosemide | Furosemide | 610 | 182 |
| Gabapentin | Gabapentin | 550 | 177 |
| Eliquis | Apixaban | 535 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 519 | 141 |
| Donepezil Hcl | Donepezil Hcl | 513 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 500 | 132 |
| Losartan Potassium | Losartan Potassium | 492 | 152 |
| Lisinopril | Lisinopril | 481 | 126 |
| Metformin Hcl | Metformin Hcl | 372 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 112 |
| Omeprazole | Omeprazole | 356 | 89 |
| Potassium Chloride | Potassium Chloride | 352 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 301 | 89 |
| Sertraline Hcl | Sertraline Hcl | 297 | 73 |
| Carvedilol | Carvedilol | 279 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 91 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 82 |
| Levofloxacin | Levofloxacin | 271 | 199 |
| Jardiance | Empagliflozin | 262 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 71 |
| Trazodone Hcl | Trazodone Hcl | 206 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 43 |
| Montelukast Sodium | Montelukast Sodium | 176 | 47 |
| Prednisone | Prednisone | 174 | 90 |
| Memantine Hcl | Memantine Hcl | 165 | 41 |
| Levetiracetam | Levetiracetam | 159 | 30 |
| Methylprednisolone | Methylprednisolone | 158 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 69 |
| Gemtesa | Vibegron | 154 | 37 |
| Allopurinol | Allopurinol | 151 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 39 |
| Tramadol Hcl | Tramadol Hcl | 146 | 62 |
| Simvastatin | Simvastatin | 144 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 126 | 31 |
| Xarelto | Rivaroxaban | 124 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 122 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 31 |
| Divalproex Sodium | Divalproex Sodium | 117 | 19 |
| Januvia | Sitagliptin Phosphate | 117 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 111 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 107 | 84 |
| Gemfibrozil | Gemfibrozil | 105 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 35 |
| Pregabalin | Pregabalin | 98 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 94 | 64 |
| Ozempic | Semaglutide | 94 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 46 |
| Mirtazapine | Mirtazapine | 89 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 22 |
| Famotidine | Famotidine | 88 | 26 |
| Warfarin Sodium | Warfarin Sodium | 87 | 14 |
| Buspirone Hcl | Buspirone Hcl | 84 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 26 |
| Clonidine Hcl | Clonidine Hcl | 77 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 24 |
| Glipizide | Glipizide | 76 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 21 |
| Alprazolam | Alprazolam | 72 | 28 |
| Spironolactone | Spironolactone | 72 | 26 |
| Finasteride | Finasteride | 71 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 20 |
| Cefdinir | Cefdinir | 68 | 60 |
| Aripiprazole | Aripiprazole | 66 | 15 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Synthroid | Levothyroxine Sodium | 63 | 16 |
| Alendronate Sodium | Alendronate Sodium | 62 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 17 |
| Atenolol | Atenolol | 59 | 20 |
| Meloxicam | Meloxicam | 58 | 25 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 14 |
| Ezetimibe | Ezetimibe | 53 | 12 |
| Repatha Sureclick | Evolocumab | 53 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | 11 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Glimepiride | Glimepiride | 50 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 18 |
| Nifedipine Er | Nifedipine | 45 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 43 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Bumetanide | Bumetanide | 43 | 24 |
| Levemir Flexpen | Insulin Detemir | 42 | 20 |
| Nystatin | Nystatin | 42 | 25 |
| Megestrol Acetate | Megestrol Acetate | 41 | 11 |
| Risperidone | Risperidone | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 33 |
| Midodrine Hcl | Midodrine Hcl | 39 | 13 |
| Primidone | Primidone | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 29 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 24 |
| Humulin R | Insulin Regular, Human | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | 11 |
| Fluconazole | Fluconazole | 35 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 19 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Phenytoin | Phenytoin | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 19 |
| Humalog | Insulin Lispro | 32 | suppressed |
| Naproxen | Naproxen | 32 | 20 |
| Vancomycin Hcl | Vancomycin Hcl | 32 | 13 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 31 | 17 |
| Acyclovir | Acyclovir | 30 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 22 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 28 | 16 |
| Topiramate Er | Topiramate | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 18 |
| Meropenem | Meropenem | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Leflunomide | Leflunomide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 15 |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 11 |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Nitroglycerin | Nitroglycerin | 20 | 18 |
| Ramipril | Ramipril | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 12 |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystop | Nystatin | 14 | 11 |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Relistor | Methylnaltrexone Bromide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Linezolid-D5w | Linezolid In Dextrose 5% | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.29 · 17 records | Sumitomo Pharma America, Inc. | Axonics, GEMTESA, JARDIANCE, JATENZO, Leqembi, MOUNJARO, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error